Napredovali MTC - izziv za zdravljenje

Show document
A+ | A- | | SLO | ENG

Title:	Napredovali MTC - izziv za zdravljenje
Authors:	ID Bergant, Damijan (Author)
Files:	PDF - Presentation file, download (136,71 KB) MD5: 792A7687154328AA9D2F4E6351756A00 PID: 20.500.12556/dirros/7f7118f6-604b-4a03-8234-7b57542c33d2
Language:	Slovenian
Typology:	1.04 - Professional Article
Organization:	OI - Institute of Oncology
Publication status:	Published
Publication version:	Version of Record
Year of publishing:	2009
Number of pages:	str. 60-63
Numbering:	Letn. 13, št. 1
PID:	20.500.12556/DiRROS-8596
UDC:	616-006
ISSN on article:	1408-1741
URN:	URN:NBN:SI:doc-B5E8Q06V
COBISS.SI-ID:	25707993
Copyright:	by Authors
Note:	BSDOCID145268;
Publication date in DiRROS:	31.08.2018
Views:	2707
Downloads:	623
Metadata:
:	Copy citation

Share:

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Title:	Onkologija. strokovni časopis za zdravnike
Shortened title:	Onkologija
Publisher:	Onkološki inštitut
ISSN:	1408-1741
COBISS.SI-ID:	65324032

License:	CC BY 4.0, Creative Commons Attribution 4.0 International

Link:	http://creativecommons.org/licenses/by/4.0/
Description:	This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:	31.08.2018

Language:	English
Title:	Advanced Medullary Thyroid Carcinoma – a Challenge for Multimodal Treatment (Case Presentation)
Abstract:	Medullary thyroid cancer is a rare, neuroendocrine, tumor. It arises from parafollicular or C-cells with the ability to produce and secrete different bioactive substances like calcitonin (TC) and CEA. MTC occurs as a sporadic tumor or in hereditary settings MEN 2A, MEN 2B and FMCT. Germ line point mutations in RET proto-oncogene are responsible for tumor rise and inheritance of settings. RET mutations diagnostics in MTC patients and their first degree relatives form the basis of genetic screening. Biological behavior of MTC shows great clinical variability. Surgery is still the treatment of choice for MTC while teleradiotherapy, chemotherapy and radioimmunotherapy are indicated in advanced disease. Molecularly targeted treatments are now part of clinical studies with some promising results. Status at admission is still the most important prognostic factor. Diagnostics, treatment - including molecularly targeted treatment and follow-up of 29-years-old patient with respiratory distress due to the advanced MTC is represented. In this case, inhibitors of receptor tyrosine kinases were used for the first time as a part of multimodal treatment of MTC at the Institute of Oncology (OI).